Showing 1,421 - 1,440 results of 1,775 for search '"Therapy"', query time: 0.09s Refine Results
  1. 1421

    Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain by Tolga Karacan, Huseyin Kiyak, Eser Ozyurek, Mevlide San, Engin Oral

    Published 2020-12-01
    “…The intensity of pain symptoms was evaluated before therapy, then after 3 and 6 months of treatment using a 10-point numerical rating scale (0 = no pain and 10 = worst possible pain) (NRS) provided to the patients in advance. …”
    Get full text
    Article
  2. 1422

    Synchrotron X-ray imaging study on the mechanism of solids transfer to bitumen froth during oil sands flotation 1: True flotation by Hanyu Zhang, Liuyin Xia, Ning Zhu, Sergey Gasilov, Iris He, Xiaofan Ding

    Published 2025-03-01
    “…The collected bitumen froth was immediately characterized using synchrotron-based X-ray imaging by a monochromatic X-ray with photon energy of 60 keV provided by 05ID-2 beamline of the BioMedical Imaging and Therapy (BMIT) facility at the Canadian Light Source (CLS). …”
    Get full text
    Article
  3. 1423

    Bufalin targets the SRC-3/c-Myc pathway in chemoresistant cells to regulate metastasis induced by chemoresistance in colorectal cancer by Jinbao Chen, Chenqi Wu, Kun Yu, Jinpei Liu, Jiahua Yang, Wei Li, Xiaoxia Tang, Yihai Shi, Ke Xu, Yi Chen, Xiaoyu Qin

    Published 2025-02-01
    “…Conclusion Bufalin can target the SRC-3/c-Myc signaling pathway to affect the prometastatic effect of chemoresistant cells, suggesting that bufalin may be used as a new adjuvant antimetastatic therapy for colorectal cancer.…”
    Get full text
    Article
  4. 1424

    Small Bowel Bacterial Overgrowth Syndrome in Patients with Bronchial Asthma by N. D. Potskhverashvili, O. Yu. Zolnikova, N. I. Kokina, N. L. Dzhakhaya, A. V. Sedova, E. L. Bueverova, A. S. Trukhmanov

    Published 2018-09-01
    “…Patients received conventional basal therapy with combined drugs (long-acting β2-adrenomimetics, and inhaled glucocorticoids). …”
    Get full text
    Article
  5. 1425

    Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study by Carmen Peral, Alfonso De Lossada Juste, Nadia Lwoff, Nataly Espinoza-Cámac, Miguel Ángel Casado, Tom Burke, Jose Alvir, Sheena Thakkar, Enrico Ferri Grazzi

    Published 2024-05-01
    “…The main direct cost component in all groups except moderate HA was factor replacement therapy. Mean per-patient indirect cost was €4089 (moderate HA), €797 (moderate HB), €8633 (severe HA) and €8049 (severe HB). …”
    Get full text
    Article
  6. 1426

    Validated HPLC method for simultaneous determination of azelastine hydrochloride fluticasone propionate and oxymetazoline in nasal mucosa and nasopharyngeal swabs from real human s... by Neven N. Mikawy, Nancy Magdy, Marwa H. Mohamed, Amira M. El-Kosasy

    Published 2025-02-01
    “…Abstract A combination of three co-administrated drugs, such as azelastine hydrochloride (AZT), fluticasone propionate (FP), and oxymetazoline (OXY), is more effective than single therapy for the treatment of seasonal allergy and COVID-19. …”
    Get full text
    Article
  7. 1427

    Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY stud... by Fuminori Taniguchi, Motoko Fukui, Yutaka Osuga, Tasuku Harada, Jo Kitawaki

    Published 2025-02-01
    “…Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, but may cause abnormal uterine bleeding. …”
    Get full text
    Article
  8. 1428

    Evaluating the risk of underdiagnosis of invasive breast cancer in needle biopsy-diagnosed ductal carcinoma in situ eligible for radiofrequency ablation by Hideo Shigematsu, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Koji Arihiro, Morihito Okada

    Published 2025-02-01
    “…Multivariate logistic regression analysis identified lesion size ≥ 10 mm as a significant risk factor for underdiagnosis (p = 0.016). Adjuvant endocrine therapy and chemotherapy were administered to 26 (65.0%) and 6 (15.0%) of the underdiagnosed lesions, respectively. …”
    Get full text
    Article
  9. 1429

    Balloon dilation for the treatment of male urethral strictures: a systematic review and meta-analysis by Tianyu Cai, Xiaoyu Li, Jian Lin, Chunru Xu, Xing Ji, Zhenpeng Zhu, Zhenke Guo

    Published 2024-02-01
    “…There is insufficient evidence to suggest that balloon dilation is superior to optical internal urethrotomy or direct visual internal urethrotomy (DVIU) (RR= 1.4754, 95% CI: 0.7306 to 2.9793, p=0.278).Conclusion Balloon dilation may be an intermediate step before urethroplasty and is a promising alternative therapy to simple dilation and DVIU. The balloon is a promising drug delivery tool, and paclitaxel drug-coated balloon dilation is effective in reducing retreatment rates in patients with recurrent anterior urethral strictures. …”
    Get full text
    Article
  10. 1430

    Two rare cases of primary clear cell adenocarcinoma of the urethra: clinical experience, case report and literature review by Bohao Jiang, Jiyuan Hu, Benqiao Wang, Xujia Liu, Ling Tong, Yitong Xu, Hao Zhang

    Published 2025-02-01
    “…The therapeutic effect of postoperative adjuvant therapies remains unclear. Future investigations on CCAU are necessary to advance clinical knowledge and to provide treatment guidance.…”
    Get full text
    Article
  11. 1431

    Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two ca... by Roberto Castelli, Enrico Atzori, Alessandro Palmerio Delitala, Salvatore Antonio Masala, Valentina Micheluzzi, Enrico Ponti, Enrico Ponti, Giuseppe Sanna, Dante Castro, Antonio Gidaro, Mattia Donadoni, Roberto Manetti, Pierluigi Merella, Nicia Isabella Profili, Andrea Maria D'Armini, Gavino Casu, Gavino Casu

    Published 2025-02-01
    “…Consequently, the patients were referred for surgical pulmonary thromboendarterectomy therapy as suggested.ConclusionIn older patients, those with a history of thrombotic manifestations, or those with high-risk factors, clinicians should evaluate and monitor the risk of thrombotic events and chronic thromboembolic pulmonary hypertension when treating primary immune thrombocytopenia with splenectomy and Eltrombopag.…”
    Get full text
    Article
  12. 1432
  13. 1433

    Health-Related Quality-of-Life Utility Values in Adults With Late-Onset Pompe Disease: Analyses of EQ-5D Data From the PROPEL Clinical Trial by Alison Griffiths, Simon Shohet, Neil Johnson, Alasdair MacCulloch

    Published 2024-09-01
    “…Clinical evidence suggests that enzyme replacement therapy improves health outcomes for adults with late-onset Pompe disease (LOPD). …”
    Get full text
    Article
  14. 1434

    Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A... by Ci Song, Peter Kunovszki, Amélie Beaudet

    Published 2022-06-01
    “…**Objectives:** To conduct retrospective database analyses to describe characteristics of patients with PAH initiating therapy with these agents and compare the rate and risk of healthcare facility encounters and drug persistence. …”
    Get full text
    Article
  15. 1435
  16. 1436

    Adaptive Neuro-Fuzzy Inference System guided objective function parameter optimization for inverse treatment planning by Eduardo Cisternas Jiménez, Fang-Fang Yin, Fang-Fang Yin, Fang-Fang Yin

    Published 2025-02-01
    “…Intensity-Modulated Radiation Therapy requires the manual adjustment to numerous treatment plan parameters (TPPs) through a trial-and-error process to deliver precise radiation doses to the target while minimizing exposure to surrounding healthy tissues. …”
    Get full text
    Article
  17. 1437

    Using positive deviance to enhance HIV care retention in South Africa: development of a compassion-focused program to improve the staff and patient experience by Allison J. Ober, Donald H. Skinner, Laura M. Bogart, Leletu Busakwe, Wadene Davids, Hassan Mahomed, Debbie Ling, Virginia Zweigenthal

    Published 2025-02-01
    “…Public primary care facilities, where most people with HIV (PWH) in South Africa receive treatment, face myriad challenges retaining patients on antiretroviral therapy (ART). Nevertheless, some facilities manage to consistently retain PWH in care. …”
    Get full text
    Article
  18. 1438

    Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting by Benjamin H. Lowentritt, Carmine Rossi, Erik Muser, Frederic Kinkead, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Shawn Du

    Published 2024-08-01
    “…**Background:** The use of androgen receptor signaling inhibitors, including apalutamide, in combination with androgen deprivation therapy is recommended for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). …”
    Get full text
    Article
  19. 1439

    Hypercalcemia and co-occurring TBX1 mutation in Glycogen Storage Disease Type Ib: case report by Zakaria Kasmi, Imane Ain El Hayat, Zahra Aadam, Abderrahmane Errami, Ibtihal Benhsaien, Jalila EL Bakkouri, Dalal Ben Sabbahia, Meryem Atrassi, Ahmed Aziz Bousfiha, Fatima Ailal

    Published 2025-01-01
    “…Initial management included a lactose-free and galactose-free diet, multivitamin supplementation, and granulocyte colony-stimulating factor (G-CSF) therapy to address neutropenia. A novel aspect of this case involves hypercalcemia as an unusual finding in GSD-Ib and the co-occurrence of a variant in the TBX1 gene, which is not typically associated with the disease but may contribute to the patient’s clinical presentation. …”
    Get full text
    Article
  20. 1440

    EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results by Tolga Taşçı, Işın Üreyen, Günsu Kimyon, Alper Karalök, Sevgi Koç, M. Faruk Köse, Gökhan Tulunay, Taner Turan

    Published 2015-08-01
    “…The effects of tumor dimension and the presence of metastasis tended to be statistically significant in determining the resistance to therapy. CONCLUSION: EMA-CO regimen is highly effective for treatment of high-risk GTN. …”
    Get full text
    Article